Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review (original) (raw)
Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence
Emmanuel Knight
Journal of Pharmacy Practice, 2019
View PDFchevron_right
Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection
Dale Gerding
Clinical Infectious Diseases
View PDFchevron_right
A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection
Chris Gentry
Open Forum Infectious Diseases, 2017
View PDFchevron_right
Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection
Sunish Shah
Hospital Pharmacy, 2018
View PDFchevron_right
Initial vancomycin for first episode non-severe Clostridium difficile infection
S. Abouanaser
View PDFchevron_right
A100 Oral Vancomycin Therapy for Clostridioides Difficile Infection and Risk of Infection with Gram-Negative Organisms
Ali Someili
Journal of the Canadian Association of Gastroenterology, 2020
View PDFchevron_right
Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections
Kathleen Mullane
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence
Konstantinos Vardakas
International Journal of Antimicrobial Agents, 2012
View PDFchevron_right
Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
Nicola Petrosillo
Antibiotics, 2022
View PDFchevron_right
A Real-World Evaluation of Oral Vancomycin for Severe Clostridium difficile Infection: Implications for Antibiotic Stewardship Programs
Miguel Salazar
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
View PDFchevron_right
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection
Chris Gentry
Journal of Clinical Pharmacy and Therapeutics, 2018
View PDFchevron_right
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease
Christina Surawicz
The American journal of gastroenterology, 2002
View PDFchevron_right
Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection
Catalin I Plesea-Condratovici
JAMA internal medicine, 2017
View PDFchevron_right
Does oral vancomycin prophylaxis during systemic antibiotic exposure prevent Clostridioides difficile infection relapses? Still in search of an answer
Rupali Jain
Infection Control & Hospital Epidemiology, 2019
View PDFchevron_right
Prospective Observational Study Comparing Three Different Treatment Regimes in Patients with Clostridium difficile Infection
Daniela Schmid
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial
Kathleen Mullane
The Journal of antimicrobial chemotherapy, 2016
View PDFchevron_right
Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
Emily Struttmann
mSphere
View PDFchevron_right
Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial
David Guttman
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017
View PDFchevron_right
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
Dale Gerding
Clinical Infectious Diseases, 2012
View PDFchevron_right
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
Chris Gentry
Clinical Microbiology and Infection, 2018
View PDFchevron_right
Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy
Russell Stafford
Gut, 1983
View PDFchevron_right
Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection
Mark Malamood, Eric Nellis
Journal of clinical medicine research, 2015
View PDFchevron_right
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
Matthew Oughton
The Lancet. Infectious diseases, 2017
View PDFchevron_right
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
Benoit Guery
The Lancet. Infectious diseases, 2018
View PDFchevron_right
Treatment of recurrent Clostridium difficile infection: a systematic review
MSc. Medicinal Chemistry 2020
Infection, 2014
View PDFchevron_right
Treating Clostridium difficile infection
S. Shafran
Canadian Medical Association Journal, 2014
View PDFchevron_right